1-20. (canceled)
21. A method for resolving invoice obligations, comprising:
providing at least one sales invoice, wherein each sales invoice comprises a credit value,
providing at least one purchase invoice, wherein each purchase invoice comprises a debit value, and
offsetting at least part of the debit value of a purchase invoice with at least part of the credit value of a sales invoice.
22. The method of claim 21, wherein the at least one sales invoice and the at least one purchase invoice form an invoice chain.
23. The method of claim 22, wherein the invoice chain is a complete chain.
24. The method of claim 22, wherein the invoice chain is a disparity chain.
25. The method of claim 22, wherein at least one determined optimal condition is utilized to determine an optimal starting point for the invoice chain.
26. The method of claim 2, wherein the invoice chain comprises an optimal invoice chain.
27. The method of claim 21, wherein at least one of the at least one sales invoice is provided by a seller, a customer or a combination thereof.
28. The method of claim 21, wherein at least one of the at least one purchase invoice is provided by a customer.
29. The method of claim 21, further comprising issuing at least one new invoice or a new balance of a partially offset invoice if the offsetting results in at least one partial fulfillment of an original invoice.
30. The method of claim 21, wherein the step of offsetting accounts for at least one currency denomination, at least one set of invoice terms and conditions or a combination thereof.
31. A method for resolving invoice obligations, comprising
providing at least one seller having at least one sales invoice,
providing at least one customer having at least one sales invoice and at least one purchase invoice, wherein at least one of the at least one sales invoice and at least one of the at least one purchase invoice forms an invoice chain; and
offsetting the at least one sales invoice of the seller with at least one sales invoice of the customer, at least one purchase invoice or a combination thereof.
32. The method of claim 31, wherein the invoice chain is a complete chain.
33. The method of claim 31, wherein the invoice chain is a disparity chain.
34. The method of claim 31, wherein at least one determined optimal condition is utilized to determine an optimal starting point for the invoice chain.
35. The method of claim 31, wherein the invoice chain comprises an optimal invoice chain.
36. A system for resolving invoice obligations, comprising:
an executable code for intelligently determining an invoice chain comprising at least one purchase invoice having a debit value and at least one sales invoice having a credit value and offsetting the debit value with the credit value,
a medium for executing the executable code,
a display device, and
an interaction tool for executing the executable code, wherein a user utilizes the interaction tool to execute the executable code.
37. The system of claim 36, wherein the medium for executing the executable code comprises a computer processor, a server system, a network system, a web-based system, the internet or a combination thereof.
38. The system of claim 36, wherein the display device comprises a computer monitor, a handheld device monitor, a television monitor, a paper or a combination thereof.
39. The system of claim 36, wherein the interaction tool comprises a series of user presets, a mouse, a keyboard, voice recognition software, touch recognition software; an application interface; integrated software or a combination thereof.
40. A software package, comprising:
an executable code for intelligently determining an invoice chain comprising at least one sales invoice having a credit value and at least one purchase invoice having a debit value and offsetting the credit value with the debit value, wherein the executable code is stored on a computer readable storage medium.
The claims below are in addition to those above.
All refrences to claims which appear below refer to the numbering after this setence.
1. A method of attenuating expression of TNFR1 mRNA of a subject in need thereof, comprising:
administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides and a pharmaceutically acceptable carrier, the interfering RNA comprising:
a sense nucleotide strand, an antisense nucleotide strand, and a region of at least near-perfect contiguous complementarity of at least 19 nucleotides;
wherein the antisense strand hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:2 beginning at nucleotide 124, 328, 387, 391, 393, 395, 406, 421, 423, 444, 447, 455, 459, 460, 467, 469, 470, 471, 475, 479, 513, 517, 531, 543, 556, 576, 587, 588, 589, 595, 601, 602, 611, 612, 651, 664, 667, 668, 669, 677, 678, 785, 786, 788, 791, 792, 804, 813, 824, 838, 843, 877, 884, 929, 959, 960, 961, 963, 964, 965, 970, 973, 974, 1000, 1002, 1013, 1026, 1053, 1056, 1057, 1058, 1161, 1315, 1318, 1357, 1360, 1383, 1393, 1420, 1471, 1573, 1671, 2044, 2045, 2046, 2047, 2048, 2089, 2090, 2091, or, 2092;
wherein the expression of TNFR1 mRNA is attenuated thereby.
2. The method of claim 1, wherein the subject is a human and the human has dry eye.
3. The method of claim 1, wherein the sense nucleotide strand and the antisense nucleotide strand are connected by a loop nucleotide strand.
4. The method of claim 1, wherein the composition is administered via an aerosol, buccal, dermal, intradermal, inhaling, intramuscular, intranasal, intraocular, intrapulmonary, intravenous, intraperitoneal, nasal, ocular, oral, otic, parenteral, patch, subcutaneous, sublingual, topical, or transdermal route.
5. The method of claim 1, wherein the interfering RNA is administered via in vivo expression from an expression vector capable of expressing the interfering RNA.
6. A method of treating a TNF\u03b1-related ocular condition in a subject in need thereof, comprising:
administering to an eye of the subject a composition beginning at an effective amount of interfering RNA having a length of 19 to 49 nucleotides, and a pharmaceutically acceptable carrier, the interfering RNA comprising a sense nucleotide strand, an antisense nucleotide strand, and the sense and antisense strands comprise a region of least near-perfect contiguous complementarity of at least 19 nucleotides;
wherein the antisense strand hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:2 comprising nucleotide 124, 328, 387, 391, 393, 395, 406, 421, 423, 444, 447, 455, 459, 460, 467, 469, 470, 471, 475, 479, 513, 517, 531, 543, 556, 576, 587, 588, 589, 595, 601, 602, 611, 612, 651, 664, 667, 668, 669, 677, 678, 785, 786, 788, 791, 792, 804, 813, 824, 838, 843, 877, 884, 929, 959, 960, 961, 963, 964, 965, 970, 973, 974, 1000, 1002, 1013, 1026, 1053, 1056, 1057, 1058, 1161, 1315, 1318, 1357, 1360, 1383, 1393, 1420, 1471, 1573, 1671, 2044, 2045, 2046, 2047, 2048, 2089, 2090, 2091, or, 2092;
wherein the TNF\u03b1-related ocular condition is treated thereby, and wherein the TNF\u03b1-related ocular condition is dry eye, allergic conjunctivitis or ocular inflammation.
7. The method of claim 6, further comprising administering to the eye of the subject a second interfering RNA having a length of 19 to 49 nucleotides and comprising:
a sense nucleotide strand, an antisense nucleotide strand, and the sense and antisense strands comprise a region of least near-perfect contiguous complementarity of at least 19 nucleotides
wherein the antisense strand of the second interfering RNA hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:1 comprising nucleotide 297, 333, 334, 335, 434, 470, 493, 547, 570, 573, 618, 649, 689, 755, 842, 844, 846, 860, 878, 894, 900, 909, 910, 913, 942, 970, 984, 1002, 1010, 1053, 1064, 1137, 1162, 1215, 1330, 1334, 1340, 1386, 1393, 1428, 1505, 1508, 1541, 1553, 1557, 1591, 1592, 1593, 1597, 1604, 1605, 1626, 1632, 1658, 1661, 1691, 1794, 1856, 1945, 1946, 1947, 1958, 2022, 2094, 2100, 2121, 2263, 2277, 2347, 2349, 2549, 2578, 2595, 2606, 2608, 2629, 2639, 2764, 2766, 2767, 2769, 3027, 3028, 3261, 3264, 3284, 3313, 3317, 3332, or 3337.
8. The method of claim 6, wherein the sense nucleotide strand and the antisense nucleotide strand are connected by a loop nucleotide strand.
9. The method of claim 6, wherein the composition is administered via an aerosol, buccal, dermal, intradermal, inhaling, intramuscular, intranasal, intraocular, intrapulmonary, intravenous, intraperitoneal, nasal, ocular, oral, otic, parenteral, patch, subcutaneous, sublingual, topical, or transdermal route.
10. The method of claim 6, wherein the interfering RNA is administered via in vivo expression from an expression vector capable of expressing the interfering RNA.
11. The method of claim 6, wherein each strand of the siRNA molecule is independently about 19 nucleotides to about 25 nucleotides in length.
12. The method of claim 6, wherein each strand of the siRNA molecule is independently about 19 nucleotides to about 21 nucleotides in length.
13. A method of attenuating expression of TACE mRNA of a subject, comprising:
administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides and a pharmaceutically acceptable carrier, the interfering RNA comprising:
a region of at least 13, 14, 15, 16, 17, or 18 contiguous nucleotides having at least 80% sequence complementarity to, or at least 90% sequence identity with, the penultimate 13 nucleotides of the 3\u2032 end of an mRNA corresponding to any one of SEQ ID NO:3, SEQ ID NO:14-SEQ ID NO:58, and SEQ ID NO:155-SEQ ID NO:201,
wherein the expression of TACE mRNA is attenuated thereby.
14. The method of claim 13, wherein the interfering RNA is one of an shRNA, an miRNA, or an siRNA.
15. The method of claim 13, wherein the composition is administered via an aerosol, buccal, dermal, intradermal, inhaling, intramuscular, intranasal, intraocular, intrapulmonary, intravenous, intraperitoneal, nasal, ocular, oral, otic, parenteral, patch, subcutaneous, sublingual, topical, or transdermal route.
16. The method of claim 13, wherein the interfering RNA is administered via in vivo expression from an expression vector capable of expressing the interfering RNA.
17. A method of treating a TNF\u03b1-related condition in a subject in need thereof, comprising:
administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides, and a pharmaceutically acceptable carrier, wherein
the interfering RNA comprises a region of at least 13, 14, 15, 16, 17, or 18 contiguous nucleotides having at least 80% sequence complementarity to, or at least 90% sequence identity with, the penultimate 13 nucleotides of the 3\u2032 end of an mRNA corresponding to any one of SEQ ID NO:3, SEQ ID NO:14-SEQ ID NO:58, and SEQ ID NO:155-SEQ ID NO:201;
wherein the TNF\u03b1-related condition is treated thereby, and wherein the TNF\u03b1-related ocular condition is dry eye, allergic conjunctivitis or ocular inflammation.
18. The method of claim 17, wherein the interfering RNA is one of an shRNA, an miRNA, or an siRNA.
19. The method of claim 17, wherein the composition is administered via an aerosol, buccal, dermal, intradermal, inhaling, intramuscular, intranasal, intraocular, intrapulmonary, intravenous, intraperitoneal, nasal, ocular, oral, otic, parenteral, patch, subcutaneous, sublingual, topical, or transdermal route.
20. The method of claim 17, wherein the interfering RNA is administered via in vivo expression from an expression vector capable of expressing the interfering RNA.